Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-center, Open-label, Single-arm Clinical Study to Evaluate the Safety and Efficacy of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3, in Children and Adolescents With Hyperchylomicronemia

NCT07371767 is registered in ClinicalTrials.gov with Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT07371767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07371767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-center, Open-label, Single-arm Clinical Study to Evaluate the Safety and Efficacy of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3, in Children and Adolescents With Hyperchylomicronemia
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
January 26, 2026
Completion date
January 31, 2041
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperchylomicronemia